Skip to main content
. 2016 Apr 11;7(20):29131–29142. doi: 10.18632/oncotarget.8675

Table 1. A674563 anti-proliferative efficacy against FLT3-ITD positive/wt intact cancer cell lines A.

Drug/Cell line GI50(μM) A674563 AZD5363 CCT128930 GDC0068 GSK690693 MK2206 TCS359 AC220
(Primary target) (AKT) (AKT) (AKT) (AKT) (AKT) (AKT) (FLT3) (FLT3)
MOLM-13
(FLT3-ITD/wt)
0.06 0.16 0.65 0.29 0.28 0.1 0.56 < 0.0003
MV4-11
(FLT3-ITD)
0.075 0.67 1 2.1 5.2 5.2 0.68 < 0.0003
MOLM-14
(FLT3-ITD/wt)
0.18 0.5 1.1 0.85 0.54 0.32 10-3 < 0.0003
OCI-AML-3
(FLT3-wt)
0.67 1.2 2.2 1.1 > 10 1.4 > 10 3–1
U937
(FLT3-wt)
0.52 0.61 4.1 0.59 5.1 7.2 > 10 0.94
NB4
(FLT3-wt)
0.48 0.93 2.5 5.9 0.22 0.21 > 10 > 10
HL-60
(FLT3-wt)
2.6 0.37 1.5 0.31 0.16 0.16 0.54 0.55
PF-382
(FLT3-wt)
2.7 0.48 1.3 0.44 0.24 0.61 > 10 0.49
SKM-1
(FLT3-wt)
2 > 10 4.3 > 10 > 10 4.6 > 10 1.3